{"id":59473,"date":"2024-02-28T05:59:35","date_gmt":"2024-02-28T05:59:35","guid":{"rendered":"https:\/\/medsname.com\/niftas\/"},"modified":"2026-04-30T11:50:31","modified_gmt":"2026-04-30T11:50:31","slug":"niftas","status":"publish","type":"product","link":"https:\/\/medsbase.com\/nl\/niftas\/","title":{"rendered":"Niftas"},"content":{"rendered":"

<\/p>\n

\n

\u26a1 Quick Answer \u2014 What is Niftas?<\/h3>\n

Niftas is a nitrofurantoin tablet for uncomplicated lower UTI in women. NOT for pyelonephritis. Avoid in CrCl < 45. Geproduceerd volgens WHO-GMP-normen.<\/p>\n<\/div>\n

Waarom bestellen bij MedsBase?<\/strong> Afkomstig van een WHO-GMP gecertificeerde fabrikant \u00b7 Discrete verpakking \u00b7 Wereldwijde verzending \u00b7 1.400+ geverifieerde klantbeoordelingen<\/a><\/div>\n

\ud83d\udce6 Elke bestelling is gedekt door onze Reshipment Assurance Policy<\/strong><\/a> \u2014 als uw pakket niet binnen 20 werkdagen arriveert, sturen wij het opnieuw.<\/p>\n

Waarom bestellen bij MedsBase<\/h3>\n

Onze generieke medicijnen zijn afkomstig van WHO-GMP gecertificeerde fabrikanten en worden wereldwijd verzonden in discrete, eenvoudige verpakkingen \u2014 geen medicijnnaam op de buitenkant van het pakket. Betalingen met kaart worden verwerkt via een gereguleerde processor (betalingsoverzichten vermelden een gereguleerde kaartbetalingprocessor \u2014 nooit \u201cMedsBase\u201d of een medicijnnaam). Crypto en SEPA bankoverschrijvingen worden ook geaccepteerd. Elke bestelling wordt ondersteund door ons Reshipment Assurance Policy.<\/p>\n

Productoverzicht<\/strong><\/h2>\n

Niftas is a medication containing the active ingredient Nitrofurantoin. It belongs to a class of antibiotics known as nitrofurans and is primarily used to treat urinary tract infections (UTIs) caused by certain bacteria. Available in both oral capsule and suspension forms, Niftas works by inhibiting the growth and reproduction of bacteria responsible for UTIs. It is commonly prescribed for both acute and chronic UTIs, providing effective relief from symptoms such as painful urination, frequent urination, and lower abdominal pain.<\/p>\n

Toepassingen<\/strong><\/h2>\n

Niftas is indicated for the treatment of urinary tract infections caused by susceptible strains of bacteria, including Escherichia coli, Enterococcus species, and Staphylococcus aureus. It is effective against both lower and upper urinary tract infections, including cystitis and pyelonephritis. Niftas works by interfering with the synthesis of bacterial cell walls, leading to bacterial cell death and resolution of the infection. It is often prescribed as a first-line treatment for uncomplicated UTIs due to its efficacy and low risk of resistance.<\/p>\n

Hoe te gebruiken<\/strong><\/h2>\n

Niftas is usually taken orally with a full glass of water, preferably with food to minimize gastrointestinal side effects. The dosage and duration of treatment will depend on the severity of the infection and the patient’s age and renal function. It is important to take Niftas exactly as prescribed by a healthcare professional and to complete the full course of treatment, even if symptoms improve before the medication is finished. Failure to do so may result in the recurrence of the infection or development of antibiotic resistance.<\/p>\n

Werking<\/strong><\/h2>\n

Nitrofurantoin, the active ingredient in Niftas, works by inhibiting the synthesis of bacterial cell walls, ultimately leading to bacterial cell death. It exerts its bactericidal effects by interfering with multiple enzymatic processes involved in the production of bacterial cell wall components. Additionally, Nitrofurantoin is capable of damaging bacterial DNA, further contributing to its antimicrobial activity. By targeting key components of bacterial cell structure and function, Niftas effectively eliminates the bacteria responsible for urinary tract infections.<\/p>\n

Dosering en toediening<\/strong><\/h2>\n

The recommended dosage of Niftas for uncomplicated urinary tract infections in adults is usually 50 to 100 mg orally four times daily for 7 days. For the prevention of recurrent urinary tract infections, a lower dosage of 50 to 100 mg orally at bedtime is often prescribed. Dosage adjustments may be necessary for patients with renal impairment, as Nitrofurantoin is primarily eliminated by the kidneys. It is important to follow the dosage instructions provided by a healthcare professional to ensure optimal treatment outcomes.<\/p>\n

Voordelen<\/strong><\/h2>\n

Niftas offers several benefits for patients with urinary tract infections. It provides effective relief from symptoms such as dysuria, urgency, and frequency associated with UTIs, improving the patient’s quality of life. Niftas is generally well-tolerated and has a low risk of systemic side effects compared to other antibiotics. Its broad spectrum of activity and convenient dosing regimen make it a preferred choice for the treatment and prevention of urinary tract infections.<\/p>\n

Veelvoorkomende bijwerkingen<\/strong><\/h2>\n

Common side effects of Niftas may include nausea, vomiting, diarrhea, abdominal pain, and headache. These side effects are usually mild and transient, resolving on their own without the need for medical intervention. However, if any side effects persist or worsen, it is important to consult a healthcare professional for further evaluation and management.<\/p>\n

Waarschuwingen<\/strong><\/h2>\n

Niftas should be used with caution in patients with known hypersensitivity to Nitrofurantoin or any other components of the formulation. It is contraindicated in patients with renal impairment, hepatic impairment, or a history of cholestatic jaundice associated with Nitrofurantoin use. Long-term use of Niftas may increase the risk of antibiotic resistance and the development of drug-resistant bacteria. It is important to discuss the risks and benefits of Niftas with a healthcare professional before starting treatment.<\/p>\n

Bewaarinformatie<\/strong><\/h2>\n

Store Niftas capsules and suspension at room temperature away from moisture and heat. Keep the medication out of reach of children and pets. Do not use Niftas beyond the expiration date printed on the packaging. If unused medication remains after completion of treatment, discard it properly according to local regulations.<\/p>\n

Disclaimer:<\/strong><\/h2>\n

Onze enige intentie is ervoor te zorgen dat consumenten informatie krijgen die deskundig beoordeeld, nauwkeurig en betrouwbaar is. De informatie hier mag echter NIET worden gebruikt als vervanging voor het advies van een gekwalificeerde arts. De verstrekte informatie is uitsluitend bedoeld voor informatieve doeleinden. Dit omvat mogelijk niet alle mogelijke bijwerkingen, geneesmiddelinteracties, waarschuwingen of meldingen. Raadpleeg uw arts en bespreek al uw vragen met betrekking tot een ziekte of medicijn. Wij willen de arts-pati\u00ebntrelatie ondersteunen, niet vervangen.<\/p>\n

Veelgestelde vragen<\/h2>\n

What is Niftas used for?<\/h3>\n

Niftas is nitrofurantoin \u2014 first-line for uncomplicated lower urinary tract infection (cystitis) in adults and older children. It concentrates in urine but achieves negligible tissue levels, so it is NOT used for pyelonephritis, prostatitis, or any non-urinary infection.<\/p>\n

Why is Niftas not used for kidney infection?<\/h3>\n

Nitrofurantoin does not achieve adequate tissue concentrations in the renal parenchyma. Pyelonephritis requires an agent that reaches systemic and renal-tissue levels (typically a fluoroquinolone, third-generation cephalosporin, or aminoglycoside).<\/p>\n

What is the typical course length?<\/h3>\n

5 days for acute uncomplicated cystitis (modern guidance, equivalent efficacy to 7-day courses with better tolerability). Long-term low-dose prophylaxis (50\u2013100 mg at night) may be used for recurrent UTI under specialist supervision.<\/p>\n

Is Niftas safe with reduced kidney function?<\/h3>\n

No \u2014 nitrofurantoin is contraindicated when creatinine clearance is below 45 mL\/min (some guidance accepts down to 30 mL\/min for short courses). Reduced renal function impairs urinary concentration AND raises systemic toxicity risk. Check renal function before each course in older patients.<\/p>\n

What serious side effects can Niftas cause with prolonged use?<\/h3>\n

Acute or chronic pulmonary fibrosis, chronic active hepatitis, and peripheral neuropathy \u2014 all rare but serious. Risk rises sharply with courses over 6 months. Annual review is mandatory if used for long-term prophylaxis.<\/p>\n

Why does Niftas turn my urine brown?<\/h3>\n

Brown or rust-coloured urine is a normal harmless effect of nitrofurantoin and its metabolites \u2014 not a sign of bleeding or kidney damage. It resolves within a few days of stopping the course.<\/p>\n

<\/p>\n

Andere anti-infectieuze medicijnen<\/h2>\n